| NCT01100112 |
(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets |
PHASE3 |
COMPLETED |
Bausch Health Americas, Inc. |
Colitis, Ulcerative |
DRUG: Budesonide |
Details |
| NCT01532648 |
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) |
PHASE3 |
COMPLETED |
Bausch Health Americas, Inc. |
Ulcerative Colitis |
DRUG: Budesonide MMX|DRUG: Placebo|DRUG: 5-ASA |
Details |
| NCT02586259 |
Effectiveness of Cortiment in Patients With Ulcerative Colitis |
None |
COMPLETED |
Ferring Pharmaceuticals |
Ulcerative Colitis |
DRUG: budesonide MMX |
Details |
| NCT00747110 |
Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC) |
PHASE3 |
COMPLETED |
Dr. Falk Pharma GmbH |
Colitis, Ulcerative |
DRUG: budesonide|DRUG: mesalazine |
Details |
| NCT05976802 |
Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis |
PHASE4 |
NOT_YET_RECRUITING |
Bausch Health Americas, Inc. |
Ulcerative Colitis |
DRUG: High dose budesonide rectal foam|DRUG: Low … |
Details |
| NCT04314375 |
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis |
PHASE4 |
RECRUITING |
Bausch Health Americas, Inc. |
Ulcerative Colitis |
DRUG: Low Dose Budesonide|DRUG: High Dose Budeson… |
Details |
| NCT00801723 |
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis. |
PHASE3 |
COMPLETED |
Bausch Health Americas, Inc. |
Ulcerative Colitis |
DRUG: Budesonide MMX 6 mg Tablet|DRUG: Placebo Ta… |
Details |
| NCT02550418 |
Budesonide 9 mg Capsules in Active UC |
PHASE2 |
COMPLETED |
Dr. Falk Pharma GmbH |
Colitis, Ulcerative |
DRUG: Budesonide |
Details |
| NCT01349673 |
The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis |
PHASE3 |
TERMINATED |
Bausch Health Americas, Inc. |
Proctitis|Proctosigmoiditis |
DRUG: Budesonide Foam |
Details |
| NCT01008423 |
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis |
PHASE3 |
COMPLETED |
Bausch Health Americas, Inc. |
Proctitis|Proctosigmoiditis |
DRUG: Budesonide|DRUG: Placebo |
Details |
| NCT01008410 |
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis |
PHASE3 |
COMPLETED |
Bausch Health Americas, Inc. |
Proctitis|Proctosigmoiditis |
DRUG: Budesonide|DRUG: Placebo |
Details |
| NL-OMON25521 |
Microbiota targeted therapy as alternative for prednisolone and biologicals in IBD patients during the current COVID-19 threat: a prospective study addressing the safety of Budesonide in combination with rifaximin or the Crohns Disease Exclusion Diet (CDED) |
Not Available |
No |
Nestlé 23/08/2021 |
None |
The results of this prospective study may result … |
Details |
| NL-OMON49003 |
A randomised controlled trial comparing FMT (fecal microbiota transplantation) after budesonide or placebo in patients with active ulcerative colitis: ;Acronym: the FECBUD trial __ - FMT for ulcerative colitis after initiation of budesonide |
Not Available |
Not Recruiting |
Leids Universitair Medisch Centrum |
inflammatory bowel disease ulcerative colitis;10… |
Intervention Patients with active ulcerative coli… |
Details |
| JPRN-UMIN000031016 |
Efficacy and safety of local budesonide for pouchitis - Efficacy of budesonide for pouchitis |
PHASE1 |
Not Recruiting |
Hyogo College of Medicine Department of Inflammatory Bowel Disease |
ulcerative colitis pouchitis |
None |
Details |
| NL-OMON44482 |
A randomised controlled trial comparing FECal Microbiota Transplantation after BUDesonide or placebo induction in patients with ulcerative colitis; the FECBUD trial__ - FMT for ulcerative colitis after initiation of budesonide |
Not Available |
None |
Haaglanden Medisch Centrum |
inflammatory bowel disease ulcerative colitis;10… |
Intervention Patients with active ulcerative coli… |
Details |
| NCT05791487 |
Combination of Diet and Oral Budesonide for Ulcerative Colitis |
None |
RECRUITING |
Wolfson Medical Center |
Ulcerative Colitis|Ulcerative Colitis Chronic Mil… |
OTHER: Ulcerative colitis Exclusion Diet|OTHER: P… |
Details |
| NCT05341401 |
Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis |
PHASE2|PHASE3 |
UNKNOWN |
Assiut University |
Ulcerative Colitis Chronic |
DRUG: Budesonide MMX|DRUG: Prednisolone |
Details |
| NCT00805285 |
The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis |
PHASE2 |
TERMINATED |
University of Maryland, Baltimore |
Inflammatory Bowel Disease|Ulcerative Colitis |
DRUG: Combination Oral Budesonide and Rectal Hydr… |
Details |
| NCT03412682 |
To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis |
PHASE3 |
COMPLETED |
Ferring Pharmaceuticals |
Colitis, Ulcerative |
DRUG: Budesonide (6 mg)|DRUG: Budesonide (9 mg)|D… |
Details |
| EUCTR2019-000852-32-NL |
A preliminary study of Low Dose Naltrexone for the induction of remission in patients with mild to moderate Crohn Disease that failed conventional treatment: The LDN Crohn study.__ - The LDN Crohn study |
PHASE2 |
Not Recruiting |
ErasmusMC |
Inflammatory Bowel Disease, Crohn's disease;Thera… |
Product Name: Naltrexone hydrochloride Pharmaceut… |
Details |
